DNA methylation of the CpG island spanning the RASSF1A promoter has been widely appreciated to associate with poor clinical outcome of non‐small cell lung cancer (Kim et al, 2003; Fischer et al, 2007). The gene discussed is RASSF1; the disease is lung cancer.